CRIS website:

We believe that CUDC-101 is the first-in-class compound under development to simultaneously inhibit HDAC, EGFR and Her2.


(November 18 in Boston)
Two-in-one antibody: Herceptin variants that target HER2 and VEGF
Germaine Fuh, Genentech, Inc., South San Francisco, CA, USA

http://www.aacr.org/home/scientists/meet...